Exploring how Cognitive Behavioral Therapy for Insomnia affects sleep and fatigue in breast cancer patients
The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients
This study is looking at how different amounts of Cognitive Behavioral Therapy for Insomnia (CBT-I) can help breast cancer patients sleep better and feel less tired during the day, with the goal of improving their overall well-being.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10433647 on NIH RePORTER |
What this research studies
This research investigates the relationship between the dosage of Cognitive Behavioral Therapy for Insomnia (CBT-I), sleep duration, and fatigue levels in patients undergoing treatment for breast cancer. It aims to understand how varying the number of CBT-I sessions can impact sleep quality and daytime fatigue, which are common issues faced by cancer patients. By focusing on the specific needs of breast cancer patients, the study seeks to provide tailored behavioral interventions that could improve their overall well-being. Participants will engage in therapy sessions designed to enhance their sleep patterns and reduce fatigue.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients experiencing insomnia and fatigue related to their diagnosis or treatment.
Not a fit: Patients who do not have breast cancer or those who do not experience insomnia or fatigue may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved sleep and reduced fatigue for breast cancer patients, enhancing their quality of life during and after treatment.
How similar studies have performed: Previous studies have shown that CBT-I can be effective for insomnia, but its application in the context of cancer-related fatigue is still being explored.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Perlis, Michael Lloyd — University of Pennsylvania
- Study coordinator: Perlis, Michael Lloyd
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.